#China Medical University #Ever Supreme #SHINE OUT

CMUH's Innovative Exosome Platform

In the forefront of spinal cord injury (SCI) treatment, China Medical University Hospital (CMUH) has collaborated with Ever Supreme International Biotechnology Co., Ltd. and SHINE OUT BIO TECHNOLOGY CO., LTD. to develop a revolutionary targeted gene-engineered exosome platform. This new innovation promises a non-invasive method for addressing acute spinal cord injuries by delivering brain-derived neurotrophic factor (BDNF) mRNA directly to lesion sites via intravenous administration.

Spinal cord injuries are a leading cause of debilitating conditions worldwide, with the World Health Organization estimating 40 to 80 cases per million people annually. Traditional treatment methods often require invasive procedures, resulting in suboptimal outcomes and long-term rehabilitation needs for numerous patients. The introduction of the mBDNF@αITG EV exosome platform is a potential game-changer in this arena, addressing two critical challenges: the invasiveness of treatment and the limited targeting capabilities of conventional exosomes.

Overview of the New Platform

The platform employs advanced nanoengineering and genetic engineering techniques to create an exosome-based delivery system designed for precise targeting of injured spinal cord tissues after intravenous injection. According to Der-Yang Cho, Superintendent at CMUH, the conventional therapies often demand direct injections into the injury site, increasing risks such as secondary trauma and the potential for infection. In contrast, the new system aims to direct therapeutic cargo non-invasively through the bloodstream to the damaged areas, thereby minimizing risks and enhancing treatment efficacy.

Ming-Chuan Li, Deputy General Manager at SHINE OUT Bio Technology, further explained that the exosomes are engineered to express a recognition ligand on their surface, allowing them to home in on regions within the injured spinal cord where the molecular marker integrin αvβ8 is upregulated. This novel targeting mechanism significantly improves the delivery accuracy of the therapeutic payload.

Dual Action: Modulates Inflammation and Enhances Repair

Upon reaching the injury site, the BDNF mRNA delivered by the αITG EV platform exhibits powerful dual action: it modulates local neuroinflammation and improves metabolic recovery. Research indicates that this system successfully shifts microglia from a pro-inflammatory state to a reparative phenotype while reducing levels of inflammatory cytokines, including TNF-α and IL-1β. This shift is critical for the subsequent recovery of neurons and overall spinal health.

Ming-You Shie, Deputy Director at the Xenotransplantation Translational Research Center at CMUH, emphasized the significance of enhancing antioxidant protein expression through the delivered BDNF mRNA. The resulting stabilization of mitochondrial dynamics contributes to reducing secondary oxidative damage often seen in spinal injuries. Researchers noted remarkable improvements in motor coordination in rat models, leading to optimism about the clinical potential of these findings.

Pathway to Commercialization and Clinical Implementation

The promising preclinical results have been documented in a publication in the Journal of Nanobiotechnology, highlighting the potential for a non-invasive approach to treating spinal cord injuries and possibly other central nervous system disorders. In January 2026, a strategic integration occurred between Ever Supreme International Biotechnology and SHINE OUT BIO TECHNOLOGY to bolster expertise and enhance production capabilities in exosome therapies tailored for central nervous system applications.

Taiwan’s regulatory framework for regenerative medicine is seen as advantageous for expediting the development and approval processes associated with these innovative therapies. As the team at CMUH moves forward with clinical trials, they are committed to navigating the regulatory landscape to provide timely access to these therapies for patients in critical need, given that